Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

ADMA Biologics FY2026 Revenue expected to be more than $625.00M vs $629.23M Est

Author: Benzinga Newsdesk | May 07, 2025 04:16pm

ADMA Biologics (NASDAQ:ADMA) FY2026 Revenue expected to be more than $625.00M vs $629.23M Est

Posted In: ADMA